Using UALCAN, gene transcript expression levels of SLCO1B1, SLCO1B3, and SLCO2B1 were shown to be significantly downregulated in the clinic-pathological characteristics (gender, nodal metastasis status, cancer stages and tumor grade) in HCC patients compared to normal counterparts. This evidence concerns the gene SLCO1B1 and hepatocellular carcinoma.